Threshold Pharmaceuticals (NASDAQ:THLD) : Investors lapped up stocks on upticks to the tune of $1.68 million in the Wednesdays trading session. The trading value on downticks was comparatively at $1.39 million and the uptick to downtick ratio of 1.21 indicates continuous buying by the bulls. The net money flow into the stock was $0.29 million. The block trades were dominated by the bulls with a healthy 1.77, uptick to downtick ratio. Only $0.22 million worth of trades exchanged hands on downticks showing the reluctance of the large traders to part with their holdings. Upticks saw transactions worth $0.38 clearly indicating buying by large investors. The total money flow for block trades stood at $0.17 million, which is a positive for the stock in the long-term. Threshold Pharmaceuticals (NASDAQ:THLD) fell $0.02 during the day at $0.6, a drop of -2.58% over the previous days close. However, for the week, the stock is 58.92%, compared to the previous week.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Senior Vice President) of Threshold Pharmaceuticals Inc, Fernandes Joel A, had purchased 3,562 shares in a transaction dated on September 28, 2015. The transaction was executed at $3.96 per share with total amount equaling $14,106. Currently the company Insiders own 13.6% of Threshold Pharmaceuticals shares according to the proxy statements. Institutional Investors own 33.98% of Threshold Pharmaceuticals shares.
The company shares have dropped -84.06% from its 1 Year high price. On Sep 18, 2015, the shares registered one year high at $5.28 and the one year low was seen on Feb 24, 2016. The 50-Day Moving Average price is $0.42 and the 200 Day Moving Average price is recorded at $0.40. Threshold Pharmaceuticals (NASDAQ:THLD): The stock opened at $0.55 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.77 for the day. The stock traded down to $0.51 during the day, due to lack of any buying support eventually closed down at $0.58 with a loss of -5.97% for the day. The stock had closed at $0.62 on the previous day. The total traded volume was 10,792,924 shares.
Threshold Pharmaceuticals, Inc. (Threshold) is a biotechnology company engaged in the discovery and development of therapeutic agents that selectively target tumor cells for the treatment of patients living with cancer. Thresholds investigational small molecule, evofosfamide, is being evaluated in two Phase III clinical trials, one registrational Phase II clinical trial and various earlier-stage clinical trials for the treatment of various diseases, such as soft tissue sarcoma, pancreatic cancer, non-squamous non-small cell lung cancer (n-s NSCLC), advanced melanoma, multiple myeloma and advanced solid tumors. Threshold has also licensed rights to a development program based on the clinical-stage oncology compound TH-4000, a hypoxia-targeted epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor. Thresholds [18F]-HX4 is an investigational Positron Emission Tomography (PET) imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.